menu
    • menu

    Company profile for Imunon

    NEW Drugs in Dev: 10
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACC...
    IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImunonUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648
    Telephone
    Telephone
    (609) 896-9100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://imunon.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IMUNON Reports Q1 2026 Financials & Business Update
    IMUNON Reports Q1 2026 Financials & Business Update

    12 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/12/3292797/0/en/imunon-reports-first-quarter-2026-financial-results-and-provides-business-update.html

    GLOBENEWSWIRE
    12 May 2026
    Share Share
    Imunon Hosts Q1 2026 Earnings Call on May 12, 2026
    Imunon Hosts Q1 2026 Earnings Call on May 12, 2026

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3287688/0/en/imunon-to-hold-first-quarter-2026-financial-results-and-business-update-conference-call-on-tuesday-may-12-2026.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    IMUNON Reveals 2025 Financials, Advances Pivotal Phase 3 Study
    IMUNON Reveals 2025 Financials, Advances Pivotal Phase 3 Study

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265395/0/en/IMUNON-Reports-2025-Financial-Results-and-Provides-Business-Update-Highlighting-Significant-Progress-with-Pivotal-Phase-3-Study.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Imunon Reports Continued Survival Gains with IMNN-001
    Imunon Reports Continued Survival Gains with IMNN-001

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262157/0/en/IMUNON-Reports-Updated-Phase-2-Data-Showing-Continued-Improvement-in-Median-Overall-Survival-with-IMNN-001-in-Women-with-Newly-Diagnosed-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    IMUNON to Host 2025 Results Call on March 31, 2026
    IMUNON to Host 2025 Results Call on March 31, 2026

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261137/0/en/IMUNON-to-Hold-2025-Financial-Results-and-Business-Update-Conference-Call-on-Tuesday-March-31-2026.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share
    Imunon Enhances Focus on Pivotal Phase 3 Ovarian Cancer Study
    Imunon Enhances Focus on Pivotal Phase 3 Ovarian Cancer Study

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232968/0/en/IMUNON-SHARPENS-FOCUS-ON-ITS-PROMISING-PIVOTAL-PHASE-3-OVARIAN-CANCER-STUDY.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search